DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 30.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.61 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cutaneous vasculitis due to ciprofloxacin. | 1992 Jul 4 |
|
| Update on prosthetic joints, dental treatment, and antibiotic prophylaxis. | 2002 Jul |
|
| Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages. | 2002 Jun |
|
| Prolonged intestinal absorption of cephradine with chitosan-coated ethylcellulose microparticles in rats. | 2002 Nov |
|
| Antimicrobial resistance pattern of Escherichia coli causing urinary tract infections, and that of human fecal flora, in the southeast of Iran. | 2002 Summer |
|
| Uptake of dipeptide and beta-lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney. | 2003 Jan 10 |
|
| Molecularly imprinted solid phase extraction-pulsed elution-mass spectrometry for determination of cephalexin and alpha-aminocephalosporin antibiotics in human serum. | 2004 Nov 15 |
|
| Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics. | 2004 Sep |
|
| Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. | 2005 Jan |
|
| Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography. | 2005 Mar-Apr |
|
| Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection. | 2005 Oct 21 |
|
| Crystal form of cephradine. | 2006 Feb |
|
| Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction. | 2006 Jul-Aug |
|
| [Genotypes of Staphylococcus aureus strains with methicillin resistant phenotype]. | 2007 May |
|
| Quantitative prediction of oral absorption of PEPT1 substrates based on in vitro uptake into Caco-2 cells. | 2008 Apr 16 |
|
| Effects of treatment with antimicrobial agents on the human colonic microflora. | 2008 Dec |
|
| Human case of Rickettsia felis infection, Taiwan. | 2008 Dec |
|
| Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. | 2008 Dec |
|
| Aeromonas salmonicida peritonitis after eating fish in a patient undergoing CAPD. | 2008 May-Jun |
|
| Pharmacokinetic study of cephradine in Pakistani healthy male volunteers. | 2008 Oct |
|
| Studies on diseased freshwater prawn Macrobrachium rosenbergii infected with Vibrio vulnificus. | 2008 Sep 1 |
|
| Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations. | 2009 |
|
| Antibiotic susceptibility of thermo-tolerant Escherichia coli 2 isolated from drinking water of Khairpur City, Sindh, Pakistan. | 2009 Apr 15 |
|
| [Kneading and dispersing manipulation in treatment of early-stage acute mastitis: a randomized controlled trial]. | 2009 Dec |
|
| Antibiotic susceptibility pattern of Staphylococcus epidermidis. | 2009 Jul |
|
| Lack of interaction between the peptidomimetic substrates captopril and cephradine. | 2009 Mar |
|
| Study on the binding behavior of lysozyme with cephalosporin analogues by fluorescence spectroscopy. | 2009 Sep |
|
| Traumatic optic neuropathy accompanying orbital grease gun injury. | 2010 Apr |
|
| Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles. | 2010 Apr 15 |
|
| Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns. | 2010 Jan |
|
| Uropathogen resistance to antibiotic prophylaxis in urinary tract infections. | 2010 Jun |
|
| Rate of conversion and complications of laparoscopic cholecystectomy in a tertiary care center in Saudi Arabia. | 2010 Mar-Apr |
|
| Rhinoscleroma: case report. | 2010 Sep-Oct |
Patents
Sample Use Guides
For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.
For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours.
For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered.
Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J01DB09
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
||
|
LIVERTOX |
178
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
||
|
NDF-RT |
N0000175488
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C47441
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
SUB21808
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
100000088255
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
D002515
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL1604
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
F1BC02I72W
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
SUB07417MIG
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
3547
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
4830
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
2239
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | RxNorm | ||
|
Cephradine
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY | |||
|
1102805
Created by
admin on Fri Dec 15 16:06:40 GMT 2023 , Edited by admin on Fri Dec 15 16:06:40 GMT 2023
|
PRIMARY |
Any of these components may be present:
ACTIVE MOIETY
SUBSTANCE RECORD
